Genocea Biosciences (GNCA) is a small cap company with a mission to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types
They have a platform called GEN-009 which is a first generation neo-antigen vaccine. The company is advancing two ATLAS-enabled programs: GEN-009, neoantigen vaccine for which they are conducting a Phase 1/2a clinical trial and expect preliminary clinical results in Q2/Q3 2020, and GEN-011, a neoantigen-specific cell therapy using T cells derived from peripheral blood, for which we intend to file an Investigational New Drug Application in the second quarter of 2020. They reported interesting data at a cancer conference in the middle of last year and shares from $4 to $11.
Now, they have a stronger cash position and shares are cheaper going into their next update — which should be in the middle of this year. This tech looks undervalued to me and has huge potential if they can continue to show good results.
Additionally, this has a “corona kicker.”
The company received a patent recently which mentions the corona virus. It’s been under the radar and not many know about it.
The corona virus angle isn’t at all why I like this company, and patents are pretty useless, but this market is running these types of plays.
So, there is an off chance the company PR’s about the patent and a big pop hits the shares.